Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 56Triple Negative Breast Neoplasms 14Sarcoma 7Neoplasm Metastasis 6Neoplasms 3HER2-negative Breast Cancer 3Carcinoma, Non-Small-Cell Lung 3Urethral Neoplasms 2Ureteral Neoplasms 2Prostatic Neoplasms 2Inflammatory Breast Neoplasms 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Liposarcoma 1Leiomyosarcoma 1Ketosis 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1

Interventions

Cisplatin 11Carboplatin 7Docetaxel 6pembrolizumab 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Cetuximab 5Trastuzumab 4Specimen Handling 4Radiotherapy 4Paclitaxel 4Sorafenib 3Nivolumab 3N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 3Lapatinib 3Goserelin 3Doxorubicin 3Capecitabine 3Biopsy 3sacituzumab govitecan 2darolutamide 2bicalutamide 2Radiotherapy, Intensity-Modulated 2Platinum 2Oxaliplatin 2Leuprolide 2Irinotecan 2Ipilimumab 2Dasatinib 2Chemotherapy, Adjuvant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Salivary Gland Neoplasms × eribulin × Clear all
NCT01613768 2018-09-28

Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer

University of Washington

Phase 2 Completed
29 enrolled 12 charts
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡